Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2020 16:05 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

Extended cash runway with $33.3 million from at-the-market equity offerings in Q4’19Focused and effective execution of clinical development of CUE-101 as a Phase 1 monotherapy dose escalation and...
March 10, 2020 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Host Business Update Call and Webcast

CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
February 26, 2020 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at Upcoming Investor Conferences in March 2020

CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
February 19, 2020 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma’s Therapeutic Immuno-STAT Platform to be Featured in Merck Presentation at Antigen-Specific Immune Tolerance Drug Development Summit

Presentation Provides Update on Immuno-STAT Platform Demonstrating Selective Modulation of Targeted T cells in Preclinical Models CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma,...
February 12, 2020 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the Biomarkers Series UK

CAMBRIDGE, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
January 21, 2020 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies

CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
December 02, 2019 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the World Vaccine & Immunotherapy Congress

CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
November 12, 2019 16:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights

Initiated patient dosing in Phase 1 clinical study of lead program CUE-101 in head and neck squamous cell carcinoma (HNSCC)Extended cash runway with $11.9 million from at-the-market equity offering in...
November 06, 2019 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at Upcoming Investor Conferences in November 2019

CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
November 05, 2019 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Host Business Update Call and Webcast

CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...